About Leap Therapeutics
Leap Therapeutics is a company based in Cambridge (United States) founded in 2011. It operates as a HealthTech. Leap Therapeutics has raised $24.68 million across 7 funding rounds from investors including BeiGene, Perceptive Advisors and Healthcare Ventures. The company has 52 employees as of December 31, 2024. Leap Therapeutics has completed 1 acquisition, including Macrocure. Leap Therapeutics offers products and services including Sirexatamab (DKN-01), FL-301, and FL-501. Leap Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 52 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Leap Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-67.56 M17.02as on Dec 31, 2024
-
EBITDA
$-70.05 M19.12as on Dec 31, 2024
-
Total Equity Funding
$24.68 M (USD)
in 7 rounds
-
Latest Funding Round
$58.9 M (USD), Post-IPO
Oct 06, 2025
-
Investors
BeiGene
& 3 more
-
Employee Count
52
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Leap Therapeutics
Leap Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LPTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Leap Therapeutics
Leap Therapeutics offers a comprehensive portfolio of products and services, including Sirexatamab (DKN-01), FL-301, and FL-501. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted therapy developed for DKK1-expressing cancer tumors.
Therapy developed for gastric and pancreatic cancer patients.
Preclinical therapy targeting GDF-15 protein for cancer.
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Finance and Accounting
3 people
Product Management Team
3 people
Chairman Team
1 people
Software Development Team
1 people
Sales and Marketing
1 people
Data Analysis and Operations Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Leap Therapeutics
Leap Therapeutics has successfully raised a total of $24.68M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $58.9 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $58.9M
-
First Round
First Round
(03 Jan 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Leap Therapeutics | Valuation |
investors |
|
| Jan, 2020 | Amount | Post-IPO - Leap Therapeutics | Valuation |
investors |
|
| Nov, 2017 | Amount | Post-IPO - Leap Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Leap Therapeutics
Leap Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include BeiGene, Perceptive Advisors and Healthcare Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed by Winklevoss brothers' family office.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Leap Therapeutics
Leap Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Macrocure. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell therapies for wound care are developed and commercialized.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Leap Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Leap Therapeutics Comparisons
Competitors of Leap Therapeutics
Leap Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Leap Therapeutics
Frequently Asked Questions about Leap Therapeutics
When was Leap Therapeutics founded?
Leap Therapeutics was founded in 2011.
Where is Leap Therapeutics located?
Leap Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Leap Therapeutics a funded company?
Leap Therapeutics is a funded company, having raised a total of $24.68M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $18M, raised on Jan 03, 2011.
How many employees does Leap Therapeutics have?
As of Dec 31, 2024, the latest employee count at Leap Therapeutics is 52.
What does Leap Therapeutics do?
Leap Therapeutics, Inc. is focused on the development of targeted and immuno-oncology therapeutics. The companys primary candidate, Sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. Additional programs include FL-301 for gastric and pancreatic cancer, and FL-501 targeting GDF-15 in preclinical stages. Solutions are aimed at addressing unmet needs in oncology through innovative therapies and combinations across multiple cancer types.
Who are the top competitors of Leap Therapeutics?
Leap Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Leap Therapeutics offer?
Leap Therapeutics offers Sirexatamab (DKN-01), FL-301, and FL-501.
Is Leap Therapeutics publicly traded?
Yes, Leap Therapeutics is publicly traded on NASDAQ under the ticker symbol LPTX.
How many acquisitions has Leap Therapeutics made?
Leap Therapeutics has made 1 acquisition, including Macrocure.
Who are Leap Therapeutics's investors?
Leap Therapeutics has 4 investors. Key investors include BeiGene, Perceptive Advisors, Healthcare Ventures, and Winklevoss Capital.
What is Leap Therapeutics's ticker symbol?
The ticker symbol of Leap Therapeutics is LPTX on NASDAQ.